Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1
Beta Met Has One

Beta Met Has One

Ratings: (0)|Views: 183|Likes:
Published by api-3797941

More info:

Published by: api-3797941 on Oct 17, 2008
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less





(bay tameth' a sone)
Topical dermatologic ointment, cream, lotion, gel:
betamethasone dipropionate
Topical dermatologic ointment, cream, lotion, aerosol:
Alphatrex, Diprolene, Diprolene AF, Diprosone, Maxivate, Taro-Sone (CAN),
betamethasone sodium phosphate
Systemic, including IV and local injection:
Betnesol (CAN), Celestone Phosphate
betamethasone sodium phosphate and acetate
Systemic, IM, and local intra-articular, intralesional, intradermal injection:
Celestone Soluspan
betamethasone valerate
Topical dermatologic ointment, cream, lotion:
Betaderm (CAN), Betatrex, Beta-Val, Betnovate (CAN), Celestoderm (CAN),
Luxiq, Prevex B (CAN), Psorion Cream, Valisone
Pregnancy Category C
Drug classes

Corticosteroid (long acting)
Hormonal agent

Therapeutic actions
Binds to intracellular corticosteroid receptors, thereby initiating many natural complex
reactions that are responsible for its anti-inflammatory and immunosuppressive effects.
Systemic administration
Hypercalcemia associated with cancer

Short-term management of inflammatory and allergic disorders, such as
rheumatoid arthritis, collagen diseases (eg SLE), dermatologic diseases (eg
pemphigus), status asthmaticus, and autoimmune disorders

Hematologic disorders: Thrombocytopenia purpura, erythroblastopenia
Ulcerative colitis, acute exacerbations of multiple sclerosis, and palliation in some
leukemias and lymphomas
Trichinosis with neurologic or myocardial involvement
Unlabeled use: Prevention of respiratory distress syndrome in premature neonates
Intra-articular or soft-tissue administration
Arthritis, psoriatic plaques, and so forth
Dermatologic preparations
Relief of inflammatory and pruritic manifestations of steroid-responsive
Contraindications and cautions
Systemic (oral and parenteral) administration
Contraindicated with infections, especially tuberculosis, fungal infections,
amebiasis, vaccinia and varicella, and antibiotic-resistant infections, lactation.
All forms

Use cautiously with kidney or liver disease, hypothyroidism, ulcerative colitis
with impending perforation, diverticulitis, active or latent peptic ulcer,
inflammatory bowel disease, CHF, hypertension, thromboembolic disorders,
osteoporosis, seizure disorders, diabetes mellitus.

Available forms

Tablets\u20140.6 mg; syrup\u20140.6 mg/5 mL; injection\u20144 mg, 3 mg betamethasone sodium phosphate with 3 mg betamethasone acetate; ointment\u20140.1%, 0.05%; cream\u20140.01%, 0.05%, 0.1%; lotion\u20140.1%, 0.05%; gel\u20140.05%

Systemic administration

Individualize dosage, based on severity and response. Give daily dose before 9 AM to minimize adrenal suppression. Reduce initial dose in small increments until the lowest dose that maintains satisfactory clinical response is reached. If long-term therapy is needed, alternate-day therapy with a short-acting corticosteroid should be considered. After long-term therapy, withdraw drug slowly to prevent adrenal insufficiency.

Oral (betamethasone): Initial dosage 0.6\u20137.2 mg/day
IV (betamethasone sodium phosphate): Initial dosage up to 9 mg/day.
IM (betamethasone sodium phosphate; betamethasone sodium phosphate and
acetate): Initial dosage 0.5\u20139 mg/day. Dosage range is one-third to one-half oral
dose given q 12 hr. In life-threatening situations, dose can be in multiples of the
oral dose.
Intrabursal, intra-articular, intradermal, intralesional (betamethasone sodium phosphate
and acetate)
0.25\u20132 mL intra-articular, depending on joint size; 0.2 mL/cm3 intradermally, not to
exceed 1 mL/wk; 0.25\u20131 mL at 3- to 7-day intervals for disorders of the foot.
Topical dermatologic cream, ointment (betamethasone dipropionate)
Apply sparingly to affected area bid\u2013qid.
Systemic administration

Individualize dosage on the basis of severity and response rather than by formulae that
correct adult doses for age or weight. Carefully observe growth and development in
infants and children on prolonged therapy.

3 days

Metabolism: Hepatic; T1/2: 36\u201354 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Unchanged in the urine

IV facts
Preparation: No further preparation needed.
Infusion: Infuse by direct IV injection over 1 min or into the tubing of running IV of
dextrose or saline solutions.
Adverse effects
CNS: Vertigo, headache, paresthesias, insomnia, seizures, psychosis, cataracts,
increased IOP, glaucoma (long-term therapy)
C V:Hypotension, shock, hypertension, and CHF secondary to fluid retention,
thromboembolism, thrombophlebitis, fat embolism, cardiac arrhythmias
Electrolyte imbalance: Na+ and fluid retention, hypokalemia, hypocalcemia
Endocrine: Amenorrhea, irregular menses, growth retardation, decreased

carbohydrate tolerance, diabetes mellitus, cushingoid state (long-term effect),
increased blood sugar, increased serum cholesterol, decreased T3 and T4 levels,
hypothalamic-pituitary-adrenal (HPA) suppression with systemic therapy longer
than 5 days

GI: Peptic or esophageal ulcer, pancreatitis, abdominal distention, nausea,
vomiting, increased appetite, weight gain (long-term therapy)
Musculoskeletal: Muscle weakness, steroid myopathy, loss of muscle mass,
osteoporosis, spontaneous fractures (long-term therapy)
Other: Immunosuppression, aggravation, or masking of infections; impaired
wound healing; thin, fragile skin; petechiae, ecchymoses, purpura, striae;
subcutaneous fat atrophy; hypersensitivity or anaphylactoid reactions
The following effects are related to various local routes of steroid administration:
Intra-articular: Osteonecrosis, tendon rupture, infection
Intralesional therapy: Blindness when applied to face and head
Topical dermatologic ointments, creams, sprays: Local burning, irritation,
acneiform lesions, striae, skin atrophy
Risk of severe deterioration of muscle strength in myasthenia gravis patients
receiving ambenonium, edrophonium, neostigmine, pyridostigmine
Decreased steroid blood levels with barbiturates, phenytoin, rifampin

Activity (7)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads
cbouray liked this
papxiao liked this
wjraffle2 liked this
BeRnAlie liked this
kaiserdark liked this

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->